Royalty Pharma
RPRX
RPRX
335 hedge funds and large institutions have $11.8B invested in Royalty Pharma in 2022 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 136 increasing their positions, 100 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
5% more funds holding
Funds holding: 318 → 335 (+17)
2% less capital invested
Capital invested by funds: $12.1B → $11.8B (-$282M)
1.3% less ownership
Funds ownership: 69.12% → 67.82% (-1.3%)
Holders
335
Holding in Top 10
9
Calls
$44.5M
Puts
$5.65M
Top Buyers
| 1 | +$45.5M | |
| 2 | +$45.2M | |
| 3 | +$40.8M | |
| 4 |
Millennium Management
New York
|
+$36.5M |
| 5 |
Renaissance Technologies
New York
|
+$34.3M |
Top Sellers
| 1 | -$133M | |
| 2 | -$116M | |
| 3 | -$46.1M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$46M |
| 5 |
Morgan Stanley
New York
|
-$37.2M |